File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen.

TitleRetracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen.
Authors
Issue Date2008
Citation
Hepatology (Baltimore, Md.), 2008, v. 48 n. 2, p. 1-10 How to Cite?
AbstractWhether preemptive anti- hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumab containing chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzumab-containing chemotherapy regimen in occult HBV-infected patients. Twenty-one consecutive occult HBV-infected patients treated with an alemtuzumab containing chemotherapy regimen were studied. T cell reactivity to HBV antigens and -peptides were quantified by ELISpot and the T cell subset by flow cytometry. Six of the 21 patients (28.6%) developed HBsAg seroreversion. The median (range) time to development of HBsAg seroreversion after the end of chemotherapy was 1.8 months (0.2-2.3 months). Direct sequencing showed that the occult HBV infection of all six patients (100%) was reactivated. These six patients developed severe HBV-related hepatitis. At the end of follow-up, four of these six patients (66.7%) had become negative for HBsAg again. Recovery of CD4+ T cell count and CD4+T cell reactivity against hepatitis B core antigen (HBcAg) occurred 9 months after the end of chemotherapy. Loss of HBsAg occurred after recovery of the CD4+T cell count and increased CD4+T cell reactivity against HBcAg 9 months after the end of chemotherapy. CONCLUSION: An alemtuzumab-containing chemotherapy regimen is associated with a high risk of reactivation of occult HBV infection. Suppression of HBV immunity by an alemtuzumab-containing chemotherapy regimen would persist until 9 months after the end of chemotherapy. In occult HBV-infected patients receiving an alemtuzumab-containing chemotherapy regimen, preemptive anti-HBV therapy should be continued until 9 months after the end of chemotherapy, when recovery of HBV immunity has occurred.
Persistent Identifierhttp://hdl.handle.net/10722/163198
ISSN
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_US
dc.contributor.authorCheung, WWen_US
dc.contributor.authorLeung, KWen_US
dc.contributor.authorCheng, VCCen_US
dc.contributor.authorTang, BSFen_US
dc.contributor.authorLi, IWSen_US
dc.contributor.authorLuk, JMen_US
dc.contributor.authorLee, NPen_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorAu, WYen_US
dc.contributor.authorYuen, KYen_US
dc.contributor.authorLau, GKen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:28:40Z-
dc.date.available2012-09-05T05:28:40Z-
dc.date.issued2008en_US
dc.identifier.citationHepatology (Baltimore, Md.), 2008, v. 48 n. 2, p. 1-10en_US
dc.identifier.issn1527-3350en_US
dc.identifier.urihttp://hdl.handle.net/10722/163198-
dc.description.abstractWhether preemptive anti- hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumab containing chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzumab-containing chemotherapy regimen in occult HBV-infected patients. Twenty-one consecutive occult HBV-infected patients treated with an alemtuzumab containing chemotherapy regimen were studied. T cell reactivity to HBV antigens and -peptides were quantified by ELISpot and the T cell subset by flow cytometry. Six of the 21 patients (28.6%) developed HBsAg seroreversion. The median (range) time to development of HBsAg seroreversion after the end of chemotherapy was 1.8 months (0.2-2.3 months). Direct sequencing showed that the occult HBV infection of all six patients (100%) was reactivated. These six patients developed severe HBV-related hepatitis. At the end of follow-up, four of these six patients (66.7%) had become negative for HBsAg again. Recovery of CD4+ T cell count and CD4+T cell reactivity against hepatitis B core antigen (HBcAg) occurred 9 months after the end of chemotherapy. Loss of HBsAg occurred after recovery of the CD4+T cell count and increased CD4+T cell reactivity against HBcAg 9 months after the end of chemotherapy. CONCLUSION: An alemtuzumab-containing chemotherapy regimen is associated with a high risk of reactivation of occult HBV infection. Suppression of HBV immunity by an alemtuzumab-containing chemotherapy regimen would persist until 9 months after the end of chemotherapy. In occult HBV-infected patients receiving an alemtuzumab-containing chemotherapy regimen, preemptive anti-HBV therapy should be continued until 9 months after the end of chemotherapy, when recovery of HBV immunity has occurred.en_US
dc.languageengen_US
dc.relation.ispartofHepatology (Baltimore, Md.)en_US
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.titleRetracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen.en_US
dc.typeArticleen_US
dc.identifier.emailLuk, JM:jmluk@hkucc.hku.hken_US
dc.identifier.emailLee, NP:nikkilee@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLuk, JM=rp00349en_US
dc.identifier.authorityLee, NP=rp00263en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid18452145en_US
dc.identifier.scopuseid_2-s2.0-50949117439en_US
dc.identifier.hkuros145637-
dc.identifier.volume48en_US
dc.identifier.issue2en_US
dc.identifier.spage1en_US
dc.identifier.epage10en_US
dc.identifier.scopusauthoridHui, CK=7202876933en_US
dc.identifier.scopusauthoridCheung, WW=8615134400en_US
dc.identifier.scopusauthoridLeung, KW=23097859100en_US
dc.identifier.scopusauthoridCheng, VC=23670479400en_US
dc.identifier.scopusauthoridTang, BS=8908243000en_US
dc.identifier.scopusauthoridLi, IW=24464179500en_US
dc.identifier.scopusauthoridLuk, JM=7006777791en_US
dc.identifier.scopusauthoridLee, NP=7402722690en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US
dc.identifier.scopusauthoridLau, GK=7102301257en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.customcontrol.immutablejt 130625-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats